Wednesday, March 21, 2018

Pascal Biosciences Inc. - PAS.v

Pascal Biosciences Inc. - PAS.v was founded in 2013 in Vancouver, based on discovery research at UBC. Pascal is a biotechnology company focused on harnessing the body’s immune system to fight cancer. Our mission is to discover and develop innovative therapeutics that empower the immune system to help patients suffering from life-threatening diseases.
On March 19, 2018 the company released News

The TSX Venture Exchange has accepted for filing documentation with respect to a non-brokered private placement announced Feb. 23, 2018, and March 8, 2018.

Number of shares: 12,875,000 shares
Purchase price: 40 cents per share
Warrants: 12,875,000 share purchase warrants to purchase 12,875,000 shares
Warrant exercise price: 60 cents for a one-year period, subject to an acceleration clause
Number of placees: 41 placees
Total pro group involvement: 3,595,000 (four placees)
On February 21, 2018 the Company released News

Pascal Biosciences Inc. (TSX.V:PAS) today announced the Company has discovered certain cannabinoids that enhance the immunogenicity of tumor cells, rendering them more susceptible to recognition by the immune system. This discovery is important because the leading class of new cancer fighting agents, termed “checkpoint inhibitors”, activates the immune system to destroy cancer cells. Enhancing recognition of cancer cells with cannabinoids may greatly improve the efficacy of this drug class. Cannabinoids are the chemical compounds which give the cannabis plant its medicinal properties with over 100 different cannabinoids identified. There is a growing body of research demonstrating the effectiveness of cannabinoids in the treatment of cancer symptoms, including nausea, appetite enhancement, and pain management. However, Pascal is the first to identify a mechanism in which cannabinoids may provide a direct benefit in immunotherapy.

Tuesday, March 20, 2018

Antibe Therapeutics Inc. - ATE.v

Antibe Therapeutics Inc. - ATE.v develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation.
On March 20, 2018 the company released NEWS

Antibe Therapeutics Inc.'s lead drug, ATB-346, met its primary end point in the phase 2B gastrointestinal safety study. The double-blind study was conducted in 244 healthy volunteers and was designed to demonstrate the superiority of ATB-346 in GI safety compared with naproxen, the most prescribed nonsteroidal anti-inflammatory drug in the United States. Subjects on ATB-346 exhibited an ulceration rate of 2.5 per cent versus an ulceration rate of 42.1 per cent for subjects on naproxen at the end of the two-week treatment period, with a very high degree of statistical significance (p was less than 0.001). ATB-346 was also safe and well tolerated.
On February 26, 2018 the company released NEWS

Antibe Therapeutics Inc. would like to confirm the previously announced timing for its Phase 2B double-blind clinical trial of ATB-346. The final subject has now completed treatment and the subsequent two-week monitoring period. The CRO conducting the study, Topstone Research Inc. , is currently performing data validation and analysis. Antibe remains on its previously announced schedule and anticipates being in a position to report top-line results during the week of March 19th, 2018.

Canada Jetlines Ltd. - JET.v

Canada Jetlines Ltd. - JET.v is set to become Canada’s first ultra-low fare airline. Jetlines was created to serve the millions of Canadians living in unserved or underserved markets across the country.
On March 13, 2018 the co released News

Canada Jetlines won't be starting operations in June

Canada Jetlines Ltd. is pleased to provide an update on certain recent corporate developments related to financing, the regulatory process, aircraft acquisition, personnel additions and launch timeline.

Monday, March 19, 2018

Klondex Mines Ltd. - KDX.t

Klondex Mines Ltd. - KDX.t is a gold and silver producer focused in North Central Nevada. The company operates three producing mineral properties: the Fire Creek Mine and the Midas Mine and ore milling facility, both in Nevada, and the True North Gold Mine (formerly the Rice Lake Mine) and mill in Manitoba.
On March 19, 2018 the media released News

Hecla Mining Company will acquire all the outstanding shares of Klondex Mines Ltd. through a plan of arrangement. Klondex's Canadian assets will be spun out to its existing shareholders.

Under the Transaction, Hecla will acquire Klondex for consideration of $462-million (U.S.) with a mix of cash and shares of Hecla common stock and the newly formed company (Klondex Canada). Klondex's shareholders will receive $2.47 (U.S.) per share in cash or shares of Hecla, which represents a 59-per-cent premium to Klondex's 30-day volume-weighted average price, as at March 16, 2018, on the NYSE American.
On February 22, 2018 the company released News

Klondex Mines Ltd. today announced the Company has increased the borrowing capacity of its credit facilities.

Sunday, March 18, 2018

Critical Elements Corporation - CRE.v

Critical Elements Corporation - CRE.v is advancing the flagship Rose Lithium-Tantalum project in Quebec.

A feasibility study suggests an after-tax NPV of $726 million (at 8% discount rate), after-tax IRR of 34.9%

On February 7, 2018 the company released News

Critical Elements Corporation is pleased to provide an update to its shareholders on the most recent discussions with strategic partners and a review of 2017 accomplishments and recent lithium market developments.

Outcropping Lemare pegmatite.